Insight Trends

AI in Precision Medicine Market Trends and Key Players

AI in Precision Medicine Market Companies, Trends and Future Analysis

The global market for Artificial Intelligence (AI) in precision medicine is projected to experience significant growth, expanding from an estimated USD 2.74 billion in 2024 to over USD 26.66 billion by 2034. This represents a robust compound annual growth rate (CAGR) of 25.54% over the forecast period.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5080

The urgent need for advanced solutions in early cancer detection is driving growth in the precision medicine market, fueled by advancements in artificial intelligence (AI). With 609,820 cancer-related deaths reported in 2023 by the National Cancer Society, the spotlight is on innovative approaches to improve outcomes.

AI is transforming precision medicine by helping identify unique patient characteristics, such as rare treatment responses or specific healthcare needs. Through advanced computational processes, AI extracts valuable insights, enhances reasoning, and supports continuous learning. This augmented intelligence enables healthcare professionals to make better-informed decisions.

Recent studies emphasize the importance of translational research in bridging AI and precision medicine, particularly in exploring how genomic and non-genomic factors interact. By integrating diverse data sources like patient symptoms, medical history, and lifestyle, AI helps streamline personalized diagnoses and improve prognostic accuracy.

Trends in the AI in Precision Medicine Market

  • Rapid advancements in machine learning and deep learning technologies, enabling more accurate predictions and diagnostics.
  • Growing adoption of AI-powered tools for cancer detection, drug development, and personalized treatment plans.
  • Increased integration of AI with genomic data for better understanding of disease mechanisms and tailored therapies.
  • Rising collaboration between AI companies, healthcare providers, and pharmaceutical firms to accelerate innovation.
  • Expansion of AI applications in rare disease management, improving diagnosis and treatment pathways.
  • Enhanced use of wearable devices and IoT in collecting real-time patient data for precision care.
  • Government initiatives and funding to support AI-driven research in precision medicine.
  • Ethical concerns and regulatory challenges driving the development of AI frameworks in healthcare.

Recent Developments in the AI in Precision Medicine Market

  • In October 2024, Aignostics secured $34 million in Series B funding to expand its product offerings for biopharmaceutical clients and accelerate its growth in the U.S. market.
  • In September 2024, researchers from Auburn University, the University of Basel, and ETH Zurich introduced a groundbreaking method that combines AI, molecular dynamic simulations, and network analysis. This innovation enhances the prediction of binding sites on the PD-L1 protein, potentially speeding up the development of personalized cancer therapies.

Key Companies in the AI in Precision Medicine Market

  • IBM
  • Microsoft
  • Google
  • NVIDIA
  • Illumina
  • Roche
  • Johnson & Johnson
  • GE Healthcare
  • Intel Corporation
  • AstraZeneca
  • Sanofi
  • Tempus

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/ai-in-precision-medicine-market-size

Access exclusive insight now @ https://www.towardshealthcare.com/price/5080

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Raj Dombe

Recent Posts

Azenta and Frenova Partner to Accelerate Genomic Research in Nephrology Through MyReason® Program

Azenta Life Sciences and Frenova, a division of Fresenius Medical Care and a leader in renal precision medicine, have announced… Read More

4 hours ago

Zenara Pharma Receives FDA Approval for First Generic Sertraline Hydrochloride Capsules with 180-Day Marketing Exclusivity

Zenara Pharma Private Limited, a leading Biophore company, has received final approval from the U.S. Food and Drug Administration (FDA)… Read More

4 hours ago

Silexion Reports Breakthrough Preclinical Results, Showing Up to 97% Inhibition in KRAS-Driven Cancer Cells

Silexion Therapeutics Corp., a global clinical-stage biotech company specializing in RNA interference (RNAi) therapies, has announced outstanding new preclinical data… Read More

4 hours ago

Genvira, Labskin, and NRC Launch Joint Canada-UK Initiative to Advance Melanoma Immunotherapies

Canada and the UK have joined forces in a groundbreaking project aimed at developing next-generation immunotherapies for malignant melanoma, a… Read More

4 hours ago

Liquid Filtration for Pharmaceutical Market Companies Driving Innovation & Growth

The liquid filtration for pharmaceutical market is rapidly evolving and is poised to generate hundreds of millions in revenue between… Read More

1 day ago

Ophthalmology Devices Market Companies Driving Growth to 2034

The global ophthalmology devices market is valued at USD 7.51 billion in 2024 and is projected to grow to USD… Read More

1 day ago